U.S. Liver Cancer Diagnostics Market Size & Outlook
Related Markets
U.S. liver cancer diagnostics market highlights
- The U.S. liver cancer diagnostics market generated a revenue of USD 3,144.2 million in 2024 and is expected to reach USD 4,440.5 million by 2033.
- The U.S. market is expected to grow at a CAGR of 3.7% from 2025 to 2033.
- In terms of segment, laboratory tests was the largest revenue generating test type in 2024.
- Laboratory Tests is the most lucrative test type segment registering the fastest growth during the forecast period.
Liver cancer diagnostics market data book summary
| Market revenue in 2024 | USD 3,144.2 million |
| Market revenue in 2033 | USD 4,440.5 million |
| Growth rate | 3.7% (CAGR from 2025 to 2033) |
| Largest segment | Laboratory tests |
| Fastest growing segment | Laboratory Tests |
| Historical data | 2021 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Laboratory Tests, Imaging, Endoscopy, Biopsy |
| Key market players worldwide | Abbott Laboratories, Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., QIAGEN N.V., Siemens Healthineers, Becton, Dickinson & Company, Illumina Inc, Epigenomics AG, Koninklijke Philips N.V., FUJIFILM Holdings Corp |
Other key industry trends
- In terms of revenue, U.S. accounted for 31.5% of the global liver cancer diagnostics market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In North America, U.S. liver cancer diagnostics market is projected to lead the regional market in terms of revenue in 2033.
- Canada is the fastest growing regional market in North America and is projected to reach USD 1,054.7 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Liver Cancer Diagnostics Market Scope
Liver Cancer Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| QIAGEN N.V. | View profile | - | - | - |
| Becton, Dickinson & Company | View profile | - | - | - |
| Koninklijke Philips N.V. | View profile | - | - | - |
| F. Hoffmann-La Roche Ltd. | View profile | - | - | - |
| Thermo Fisher Scientific, Inc. | View profile | - | - | - |
| Siemens Healthineers | View profile | 10001+ | Malvern, Pennsylvania, United States, North America | https://www.siemens-healthineers.com |
| Epigenomics AG | View profile | 18 | Geneststrasse 5, Berlin, BB, Germany, 10829 | https://www.epigenomics.com |
| Illumina Inc | View profile | 9300 | 5200 Illumina Way, San Diego, CA, United States, 92122 | https://www.illumina.com |
| FUJIFILM Holdings Corp | View profile | 83784 | 7-3, Akasaka 9-chome, Minato-ku, Tokyo, Japan, 107-0052 | http://www.fujifilmholdings.com |
| Abbott Laboratories | View profile | 114000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | https://www.abbottinvestor.com |
U.S. liver cancer diagnostics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to liver cancer diagnostics market will help companies and investors design strategic landscapes.
Laboratory tests was the largest segment with a revenue share of 42.34% in 2024. Horizon Databook has segmented the U.S. liver cancer diagnostics market based on laboratory tests, imaging, endoscopy, biopsy covering the revenue growth of each sub-segment from 2021 to 2033.
The U.S. liver cancer diagnostics market is projected to grow in the period 2025-2030. This growth is driven by the increasing prevalence of liver cancer, advancements in diagnostic technologies such as AI-assisted imaging and liquid biopsy, and the presence of key players like Abbott Laboratories, Thermo Fisher Scientific, Illumina, and Guardant Health.
Moreover, ongoing research aimed at developing innovative diagnostic products will provide additional lucrative opportunities throughout the forecast period. Innovations in non-invasive testing and personalized medicine are enhancing early detection and treatment precision, positioning the U.S. as a leader in the global market.
Reasons to subscribe to U.S. liver cancer diagnostics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. liver cancer diagnostics market databook
-
Our clientele includes a mix of liver cancer diagnostics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. liver cancer diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into U.S. liver cancer diagnostics market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. liver cancer diagnostics market size, by test type, 2021-2033 (US$M)
U.S. Liver Cancer Diagnostics Market Outlook Share, 2024 & 2033 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
